Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz HJ, Raoul JL, Meropol NJ, Lombard-Bohas C, Posey J, Faivre S, Raymond E, Valle JW. Lamarca A, et al. Among authors: kulke m. Br J Cancer. 2018 Jan;118(2):181-188. doi: 10.1038/bjc.2017.402. Epub 2017 Nov 21. Br J Cancer. 2018. PMID: 29161241 Free PMC article.
Neuroendocrine tumors.
Clark OH, Ajani J, Benson AB 3rd, Byrd D, Doherty GM, Engstrom PF, Ettinger DS, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kvols L, Nemcek AA Jr, Olson JA Jr, Ratliff TW, Saltz L, Schteingart DE, Shah MH, Shibata S; National Comprehensive Cancer Network. Clark OH, et al. Among authors: kulke mh. J Natl Compr Canc Netw. 2006 Feb;4(2):102-38. doi: 10.6004/jnccn.2006.0013. J Natl Compr Canc Netw. 2006. PMID: 16451769 Review. No abstract available.
Activity of sunitinib in patients with advanced neuroendocrine tumors.
Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Kulke MH, et al. J Clin Oncol. 2008 Jul 10;26(20):3403-10. doi: 10.1200/JCO.2007.15.9020. J Clin Oncol. 2008. PMID: 18612155 Clinical Trial.
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Yao JC, et al. Among authors: kulke mh. J Clin Oncol. 2010 Jan 1;28(1):69-76. doi: 10.1200/JCO.2009.24.2669. Epub 2009 Nov 23. J Clin Oncol. 2010. PMID: 19933912 Free PMC article. Clinical Trial.
279 results